Coherus And Junshi Biosciences Announce FDA Approval Of LOQTORZI In All Lines Of Treatment For Recurrent Or Metastatic Nasopharyngeal Carcinoma
Portfolio Pulse from Benzinga Newsdesk
Coherus and Junshi Biosciences have announced that the FDA has approved LOQTORZI for all lines of treatment for recurrent or metastatic nasopharyngeal carcinoma. LOQTORZI is the first and only FDA-approved treatment for this type of cancer. It is indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status.
October 27, 2023 | 7:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coherus, symbol CHRS, has received FDA approval for LOQTORZI, a treatment for nasopharyngeal carcinoma. This approval could potentially increase the company's market share and revenues.
The FDA approval of LOQTORZI, a treatment for nasopharyngeal carcinoma, is a significant milestone for Coherus. This approval opens up a new market for the company, potentially increasing its market share and revenues. Given the fact that LOQTORZI is the first and only FDA-approved treatment for this type of cancer, it could give Coherus a competitive advantage in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100